These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 23263526)
1. From genetic association studies to the biology of interleukin-28B in hepatitis C virus infection and beyond. Lange CM Gut; 2013 Sep; 62(9):1246-7. PubMed ID: 23263526 [No Abstract] [Full Text] [Related]
2. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b. Hashimoto Y; Ochi H; Abe H; Hayashida Y; Tsuge M; Mitsui F; Hiraga N; Imamura M; Takahashi S; Nelson Hayes C; Ohishi W; Kubo M; Tsunoda T; Kamatani N; Nakamura Y; Chayama K J Med Virol; 2011 Jun; 83(6):981-8. PubMed ID: 21503910 [TBL] [Abstract][Full Text] [Related]
3. Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype. Huang CF; Yu ML; Kao JH; Tseng TC; Yeh ML; Huang JF; Dai CY; Lin ZY; Chen SC; Wang LY; Juo SH; Chuang WL; Liu CH J Clin Virol; 2013 Apr; 56(4):293-8. PubMed ID: 23246359 [TBL] [Abstract][Full Text] [Related]
4. Effect of interleukin-28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with pegylated interferon alpha-2a/ribavirin. Pearlman BL; Ehleben C Hepatology; 2012 May; 55(5):1645. PubMed ID: 22212908 [No Abstract] [Full Text] [Related]
5. [PROGNOSTIC VALUE OF THE COMBINATION OF BLOOD GROUP SPECIFICITY AND INTERLEUKIN 28B GENE POLYMORPHISM FOR ESTIMATION OF EFFICIENCY OF THERAPY WITH THE USE OF PEGYLATED INTERFERON α-2 AND RIBAVARIN IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C]. Ogurtsov PP; Kukhareva EI Klin Med (Mosk); 2016; 94(3):224-30. PubMed ID: 27522730 [TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients. Mira JA; Rivero A; de Los Santos-Gil I; López-Cortés LF; Girón-González JA; Márquez M; Merino D; del Mar Viloria M; Téllez F; Ríos-Villegas MJ; Omar M; Rivero-Juárez A; Macías J; Pineda JA; AIDS; 2012 Aug; 26(13):1721-4. PubMed ID: 22695304 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of pegylated interferon α-2b and ribavirin in chronic hepatitis C virus (genotypes 1 and 4) infection. Wiśniewska-Ligier M; Pawłowska M; Pilarczyk M; Halota W; Woźniakowska-Gęsicka T J Pediatr Gastroenterol Nutr; 2013 Dec; 57(6):694-9. PubMed ID: 23942001 [TBL] [Abstract][Full Text] [Related]
9. Peginterferon and ribavirin for chronic hepatitis C. Hoofnagle JH; Seeff LB N Engl J Med; 2006 Dec; 355(23):2444-51. PubMed ID: 17151366 [No Abstract] [Full Text] [Related]
10. Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes. Honda M; Shirasaki T; Shimakami T; Sakai A; Horii R; Arai K; Yamashita T; Sakai Y; Yamashita T; Okada H; Murai K; Nakamura M; Mizukoshi E; Kaneko S Hepatology; 2014 Mar; 59(3):828-38. PubMed ID: 24311440 [TBL] [Abstract][Full Text] [Related]
11. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype. Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698 [TBL] [Abstract][Full Text] [Related]
12. Chronic hepatitis C: viral clearance several months after discontinuation of therapy in two non-responders. Denis J; Rautou PE; Lambare B; Herbert S; Auray-Cartier V; Asselah T Infection; 2007 Jun; 35(3):197-200. PubMed ID: 17565465 [TBL] [Abstract][Full Text] [Related]
14. [Gene expression profiling in the first twelve weeks of treatment in chronic hepatitis C patients]. Jiménez-Sousa MÁ; Almansa R; de la Fuente C; Caro-Patón A; Ruiz L; Sánchez-Antolín G; González JM; Aller R; Alcaide N; Largo P; Ortiz de Lejarazu R; Bermejo-Martín JF Enferm Infecc Microbiol Clin; 2011 Oct; 29(8):573-80. PubMed ID: 21722999 [TBL] [Abstract][Full Text] [Related]
15. Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C. Bronowicki JP; Pol S; Thuluvath PJ; Larrey D; Martorell CT; Rustgi VK; Morris DW; Younes Z; Fried MW; Bourlière M; Hézode C; Reddy KR; Massoud O; Abrams GA; Ratziu V; He B; Eley T; Ahmad A; Cohen D; Hindes R; McPhee F; Reilly B; Mendez P; Hughes E Antivir Ther; 2013; 18(7):885-93. PubMed ID: 23804631 [TBL] [Abstract][Full Text] [Related]
16. Interaction between calcineurin inhibitors and IL-28B rs12979860 C>T polymorphism and response to treatment for post-transplant recurrent hepatitis C. Bitetto D; De Feo T; Mantovani M; Falleti E; Fabris C; Belli LS; Fagiuoli S; Burra P; Piccolo G; Donato MF; Toniutto P; ; Cmet S; Cussigh A; Viganò R; Airoldi A; Pasulo L; Colpanij M; De Martin E; Gambato M; Rigamonti C Dig Liver Dis; 2013 Nov; 45(11):927-32. PubMed ID: 23722013 [TBL] [Abstract][Full Text] [Related]
17. Early virological response in children with chronic hepatitis C treated with pegylated interferon and ribavirin. Kowala-Piaskowska A; Słuzewski W; Figlerowicz M; Mozer-Lisewska I Infection; 2007 Jun; 35(3):175-9. PubMed ID: 17565459 [TBL] [Abstract][Full Text] [Related]
18. Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1. Amanzada A; Schneider S; Moriconi F; Lindhorst A; Suermann T; van Thiel DH; Mihm S; Ramadori G J Med Virol; 2012 Aug; 84(8):1208-16. PubMed ID: 22711348 [TBL] [Abstract][Full Text] [Related]
19. [Early virologic response in retherapy with pegylated interferon alpha-2B plus ribavirin in children with chronic hepatitis C]. Pawłowska M; Palewicz E; Halota W Przegl Epidemiol; 2006; 60(1):71-7. PubMed ID: 16758742 [TBL] [Abstract][Full Text] [Related]